Last reviewed · How we verify

NCT04101500

Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD).

Status unknown Phase 4 Last updated 24 September 2019
What this trial tests

Phase 4 trial testing Compound Ipratropium Bromide Solution(C1) for Inhalation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in 200 participants. Status unknown.

Timeline
1 April 2019
Primary endpoint
30 December 2020
30 December 2024

Quick facts

Lead sponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment200
Start date1 April 2019
Primary completion30 December 2020
Estimated completion30 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 40 to 70, any sex, with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an important event in the management of chronic obstructive pulmonary disease. Compound sodium chlolate and aminophylline tablets are one of the most widely used drugs for the treatment of bronchial asthma and chronic bronchitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04101500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing